CTOs on the Move

Alexion Pharmaceuticals

www.alexion.com

 
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.alexion.com
  • 100 College Street
    New Haven, CT USA 06510
  • Phone: 203.271.8198

Executives

Name Title Contact Details
Rick Braun
Associate Director, Go-to-Market IT Business Partner Profile
Lauren Iacono
Head of Digital and Social Communications Profile
Craig Mansfield
Director, Global Head of Security and Facilities Operations Profile
Frederic Lancaster
Deputy Chief Information Security Officer Profile
Susan Tyson
Associate Director - Security Business Solutions Profile

Similar Companies

Omni Environmental Services

Omni Environmental Services is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZIOPHARM Oncology

ZIOPHARM Oncology is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Biotech Associates

Southern Biotech Associates is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karius

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.

CiVi Biopharma

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.